Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

A Randomized Phase II Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07594431

Enrollment

Registered

2026-05-18

Start date

2026-08-01

Completion date

2028-08-01

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastases, Metastatic Cancer

Keywords

LATTICE Radiotherapy, Palliative Radiotherapy

Brief summary

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Interventions

RADIATIONLATTICE Radiotherapy

5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

RADIATIONStandard radiotherapy

Standard radiotherapy delivered to 25 Gy in 5 fractions.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

80 patients with confirmed metastatic tumor (\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included. Inclusion Criteria: * Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer * One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis * Age ≥12 * ECOG Performance Status 0-2 * For patients age 12-16, Lansky Play-Performance score 50-100 * Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential * All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

Exclusion criteria

* Prior radiation therapy to the tumor to be treated * Active pregnancy * Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome * The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Design outcomes

Primary

Measure	Time frame	Description
Percent Tumor Volume Reduction Following Radiotherapy	90 +/- 20 days following radiotherapy	Radiographic response defined as percent tumor volume reduction 90 +/- 20 days following radiotherapy

Countries

United States

Contacts

CONTACTJamie Wang

jwang97@stanford.edu650-497-4354

CONTACTCamellia Djebroun

cdjebrou@stanford.edu650-736-5564

PRINCIPAL_INVESTIGATORMichael Gensheimer, MD

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026